Adhesion of PLGA or Eudragit®/PLGA nanoparticles to Staphylococcus and Pseudomonas

Dillen, Kathleen; Bridts, Chris H.; Veken, Pieter Van der; Cos, Paul; Vandervoort, Jo; Augustyns, Koen; Stevens, W. J.; Ludwig, Annick

doi:10.1016/j.ijpharm.2007.07.041

Cited by 59 publications

(31 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interactions between nanoparticles and bacterial membranes can improve the therapeutic drug effects, providing membrane disruption and leading to antimicrobial activity. 20,23,55 Aiming to observe nanoparticle adhesion on bacterial membrane, Dillen et al 23 discussed the strong interactions between nanoparticles (formed by EUDRAGIT ® and PLGA + EUDRAGIT ® ) and bacterial membranes of S. aureus and P. aeruginosa. The authors showed that the interaction between cationic nanoparticles formed by EUDRAGIT ® probably provides an enhanced electrostatic interaction, making a better adhesion to microorganisms than anionic PLGA nanoparticles.…”

Section: In Vivo Antibacterial Analysismentioning

confidence: 99%

“…The authors showed that the interaction between cationic nanoparticles formed by EUDRAGIT ® probably provides an enhanced electrostatic interaction, making a better adhesion to microorganisms than anionic PLGA nanoparticles. 23 Nanoparticles were here produced by using EUDRAGIT ® L 100-55, an anionic polymer and EUDRAGIT ® RS 30 D, a polymer with a quaternary ammonium group responsible for making polymer permeability. 17,19 Immunomodulatory assays ( Figure 4B and C) showed that nanostructures without 19,57 which is an important point in sepsis medicine, since they can provide a systemic inflammatory response syndrome (SIRS) control, avoiding septic shock.…”

Section: In Vivo Antibacterial Analysismentioning

confidence: 99%

“…This assay provides information about storage stability, since the nanostructures were only applied to water environment. 23 Bi et al 24 developed phytoglycogen-based nanoparticles containing the antimicrobial peptide nisin, effective against Listeria monocytogenes. Furthermore, Liu et al 25 showed core-shell nanostructured nanoparticles formed from TAT sequence (YGRKKRRQRRR) against S. aureus.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clavanin bacterial sepsis control using a novel methacrylate nanocarrier

Saúde¹,

Ombredane²,

Silva³

et al. 2014

IJN

View full text Add to dashboard Cite

Controlling human pathogenic bacteria is a worldwide problem due to increasing bacterial resistance. This has prompted a number of studies investigating peptides isolated from marine animals as a possible alternative for control of human pathogen infections. Clavanins are antimicrobial peptides isolated from the marine tunicate Styela clava , showing 23 amino acid residues in length, cationic properties, and also high bactericidal activity. In spite of clear benefits from the use of peptides, currently 95% of peptide properties have limited pharmaceutical applicability, such as low solubility and short half-life in the circulatory system. Here, nanobiotechnology was used to encapsulate clavanin A in order to develop nanoantibiotics against bacterial sepsis. Clavanin was nanostructured using EUDRAGIT ® L 100-55 and RS 30 D solution (3:1 w:w). Atomic force, scanning electron microscopy and dynamic light scattering showed nanoparticles ranging from 120 to 372 nm in diameter, with a zeta potential of -7.16 mV and a polydispersity index of 0.123. Encapsulation rate of 98% was assessed by reversed-phase chromatography. In vitro bioassays showed that the nanostructured clavanin was partially able to control development of Staphylococcus aureus , Klebsiella pneumoniae , and Pseudomonas aeruginosa . Furthermore, nanostructures did not show hemolytic activity. In vivo sepsis bioassays were performed using C57BL6 mice strain inoculated with a polymicrobial suspension. Assays led to 100% survival rate under sub-lethal sepsis assays and 40% under lethal sepsis assays in the presence of nanoformulated clavanin A until the seventh day of the experiment. Data here reported indicated that nanostructured clavanin A form shows improved antimicrobial activity and has the potential to be used to treat polymicrobial infections.

show abstract

Section: In Vivo Antibacterial Analysismentioning

confidence: 99%

Section: In Vivo Antibacterial Analysismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clavanin bacterial sepsis control using a novel methacrylate nanocarrier

Saúde¹,

Ombredane²,

Silva³

et al. 2014

IJN

View full text Add to dashboard Cite

show abstract

“…PLGA (Resomer® RG 503 H) with the molecular weight of 34,000 Da and inherent viscosity of 0.32-0.44 dl/g has uncapped (free) carboxyl termini (17). In recent years, engineering approaches have been devised to create novel micro-and nano-particles which provide greater control over the drug release profile and present opportunities for drug targeting at the tissue and cellular levels (18,19).…”

Section: Introductionmentioning

confidence: 99%

Formulation and In vitro Characterization of Eudragit® L100 and Eudragit® L100-PLGA Nanoparticles Containing Diclofenac Sodium

2010

View full text Add to dashboard Cite

Abstract. The aim of this study was to formulate and characterize Eudragit® L100 and Eudragit® L100-poly(lactic-co-glycolic acid) (PLGA) nanoparticles containing diclofenac sodium. Diclofenac generates severe adverse effects with risks of toxicity. Thus, nanoparticles were prepared to reduce these drawbacks in the present study. These nanoparticles were evaluated for surface morphology, particle size and size distribution, percentage drug entrapment, and in vitro drug release in pH 6.8. The prepared nanoparticles were almost spherical in shape, as determined by atomic force microscopy. The nanoparticles with varied size (241-274 nm) and 25.8-62% of entrapment efficiency were obtained. The nanoparticles formulations produced the release profiles with an initial burst effect in which diclofenac sodium release ranged between 38% and 47% within 4 h. The extent of drug release from Eudragit® L100 nanoparticles was up to 92% at 12 h. However, Eudragit®/PLGA nanoparticles showed an initial burst release followed by a slower sustained release. The cumulative release at 72 h was 56%, 69%, and 81% for Eudragit®/PLGA (20:80), Eudragit®/PLGA (30:70) and Eudragit®/PLGA (50:50) nanoparticles, respectively. The release profiles and encapsulation efficiencies depended on the amount of Eudragit in the blend. These data demonstrated the efficacy of these nanoparticles in sustaining the diclofenac sodium release profile.

show abstract

“…The higher antibacterial effect of clarithromycin and azithromycin may have resulted from higher bacterial adhesion of the nanoparticles. For example, an adhesion of Eudragit nanoparticles containing PLGA to the S. aureus bacteria was reported (83). Although, Figure 4 shows that the ratio of drug:PLGA has no significant effect on antibacterial activity of azithromycin and clarithromycin, Table 1 shows that the particle size of nanoparticles, their zeta potential and the encapsulation efficiency are remarkably dependent on the ratio of drug:polymer used in the formulations.…”

Section: Antibiotic Loaded Plga Nanoparticlesmentioning

confidence: 99%